Bisphosphonates in patients with renal cell carcinoma and bone metastases: A sunitinib global expanded-access trial subanalysis

Eduard Vrdoljak; Martin Gore; Sophie Leyman; Cezary Szczylik; Galina Kharkevich; Patrick Schöffski; Laszlo Torday; Josef Mardiak; Ke Zhang; Peter Sajben; Avishay Sella

doi:10.2217/fon.15.140

Bisphosphonates in patients with renal cell carcinoma and bone metastases: A sunitinib global expanded-access trial subanalysis

Eduard Vrdoljak, Martin Gore, Sophie Leyman, Cezary Szczylik, Galina Kharkevich, Patrick Schöffski, Laszlo Torday, Josef Mardiak, Ke Zhang, Peter Sajben, Avishay Sella

Research output: Contribution to journal › Article › peer-review

8 Scopus citations

Abstract

Aim: To investigate retrospectively the effects of bone metastases and bisphosphonates in sunitinib-treated metastatic renal cell carcinoma patients. Patients & methods: Patients in Groups (Gp) 1 and 2, but not Gp3, had bone metastases. Gp2 received bisphosphonates following standard practice. Results: Gp2 had less favorable prognosis than Gp1. Gp3 had fewer metastases and the best prognosis. More serious adverse events occurred in Gp2 versus Gp1. The difference in overall survival between Gp1 and Gp2 was not significant after adjusting for covariates. Significantly shorter overall survival in Gp1 versus Gp3 persisted after adjusting for covariates. Conclusion: Bone metastases may have a negative prognostic impact in metastatic renal cell carcinoma. Bisphosphonates may have delayed early disease progression for prognostically worse sunitinib/bisphosphonate-treated patients.

Original language	English
Pages (from-to)	2831-2840
Number of pages	10
Journal	Future Oncology
Volume	11
Issue number	20
DOIs	https://doi.org/10.2217/fon.15.140
State	Published - Oct 2015
Externally published	Yes

Keywords

VEGF
angiogenesis inhibitor
metastasis
pamidronate
renal cell carcinoma
sunitinib
zoledronic acid

Access to Document

10.2217/fon.15.140

Cite this

@article{bb746d63b4aa423896a310ce507c08f9,

title = "Bisphosphonates in patients with renal cell carcinoma and bone metastases: A sunitinib global expanded-access trial subanalysis",

abstract = "Aim: To investigate retrospectively the effects of bone metastases and bisphosphonates in sunitinib-treated metastatic renal cell carcinoma patients. Patients & methods: Patients in Groups (Gp) 1 and 2, but not Gp3, had bone metastases. Gp2 received bisphosphonates following standard practice. Results: Gp2 had less favorable prognosis than Gp1. Gp3 had fewer metastases and the best prognosis. More serious adverse events occurred in Gp2 versus Gp1. The difference in overall survival between Gp1 and Gp2 was not significant after adjusting for covariates. Significantly shorter overall survival in Gp1 versus Gp3 persisted after adjusting for covariates. Conclusion: Bone metastases may have a negative prognostic impact in metastatic renal cell carcinoma. Bisphosphonates may have delayed early disease progression for prognostically worse sunitinib/bisphosphonate-treated patients.",

keywords = "VEGF, angiogenesis inhibitor, metastasis, pamidronate, renal cell carcinoma, sunitinib, zoledronic acid",

author = "Eduard Vrdoljak and Martin Gore and Sophie Leyman and Cezary Szczylik and Galina Kharkevich and Patrick Sch{\"o}ffski and Laszlo Torday and Josef Mardiak and Ke Zhang and Peter Sajben and Avishay Sella",

note = "Publisher Copyright: {\textcopyright} 2015 Future Medicine Ltd.",

year = "2015",

month = oct,

doi = "10.2217/fon.15.140",

language = "אנגלית",

volume = "11",

pages = "2831--2840",

journal = "Future Oncology",

issn = "1479-6694",

publisher = "Future Medicine Ltd.",

number = "20",

}

TY - JOUR

T1 - Bisphosphonates in patients with renal cell carcinoma and bone metastases

T2 - A sunitinib global expanded-access trial subanalysis

AU - Vrdoljak, Eduard

AU - Gore, Martin

AU - Leyman, Sophie

AU - Szczylik, Cezary

AU - Kharkevich, Galina

AU - Schöffski, Patrick

AU - Torday, Laszlo

AU - Mardiak, Josef

AU - Zhang, Ke

AU - Sajben, Peter

AU - Sella, Avishay

PY - 2015/10

Y1 - 2015/10

N2 - Aim: To investigate retrospectively the effects of bone metastases and bisphosphonates in sunitinib-treated metastatic renal cell carcinoma patients. Patients & methods: Patients in Groups (Gp) 1 and 2, but not Gp3, had bone metastases. Gp2 received bisphosphonates following standard practice. Results: Gp2 had less favorable prognosis than Gp1. Gp3 had fewer metastases and the best prognosis. More serious adverse events occurred in Gp2 versus Gp1. The difference in overall survival between Gp1 and Gp2 was not significant after adjusting for covariates. Significantly shorter overall survival in Gp1 versus Gp3 persisted after adjusting for covariates. Conclusion: Bone metastases may have a negative prognostic impact in metastatic renal cell carcinoma. Bisphosphonates may have delayed early disease progression for prognostically worse sunitinib/bisphosphonate-treated patients.

AB - Aim: To investigate retrospectively the effects of bone metastases and bisphosphonates in sunitinib-treated metastatic renal cell carcinoma patients. Patients & methods: Patients in Groups (Gp) 1 and 2, but not Gp3, had bone metastases. Gp2 received bisphosphonates following standard practice. Results: Gp2 had less favorable prognosis than Gp1. Gp3 had fewer metastases and the best prognosis. More serious adverse events occurred in Gp2 versus Gp1. The difference in overall survival between Gp1 and Gp2 was not significant after adjusting for covariates. Significantly shorter overall survival in Gp1 versus Gp3 persisted after adjusting for covariates. Conclusion: Bone metastases may have a negative prognostic impact in metastatic renal cell carcinoma. Bisphosphonates may have delayed early disease progression for prognostically worse sunitinib/bisphosphonate-treated patients.

KW - VEGF

KW - angiogenesis inhibitor

KW - metastasis

KW - pamidronate

KW - renal cell carcinoma

KW - sunitinib

KW - zoledronic acid

UR - http://www.scopus.com/inward/record.url?scp=84944753188&partnerID=8YFLogxK

U2 - 10.2217/fon.15.140

DO - 10.2217/fon.15.140

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

C2 - 26118456

AN - SCOPUS:84944753188

SN - 1479-6694

VL - 11

SP - 2831

EP - 2840

JO - Future Oncology

JF - Future Oncology

IS - 20

ER -

Bisphosphonates in patients with renal cell carcinoma and bone metastases: A sunitinib global expanded-access trial subanalysis

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this